Abstract | BACKGROUND AND AIMS: METHODS:
CT-P13 and infliximab were investigated and compared by in vitro experiments for their neutralisation ability of soluble tumour necrosis factor alpha [sTNFα] and membrane-bound tumour necrosis factor alpha [mTNFα], suppression of cytokine release by reverse signalling, induction of regulatory macrophages and wound healing, and antibody-dependent cell cytotoxicity [ADCC]. RESULTS:
CT-P13 showed similar biological activities to infliximab as gauged by neutralisation of soluble TNFα, as well as blockade of apoptosis and suppression of pro-inflammatory cytokines in intestinal Caco-2 cells. Infliximab and CT-P13 equally induced apoptosis and outside-to-inside signals through transmembrane TNFα [tmTNFα]. Moreover, regulatory macrophage induction and ensuing wound healing were similarly exerted by CT-P13 and infliximab. However, neither CT-P13 nor infliximab exerted any significant ADCC of ex vivo-stimulated peripheral blood monocytes or lamina propria mononuclear cells from IBD patients. CONCLUSIONS: These findings indicate that CT-P13 and infliximab exert highly similar biological activities in intestinal cells, and further support a mechanistic comparability of these two drugs in the treatment of IBD.
|
Authors | Ki Jung Lim, So Jung Lee, Sunghwan Kim, Su Yeon Lee, Min Seob Lee, Yoon A Park, Eun Jin Choi, Eun Beom Lee, Hwang Keun Jun, Jong Moon Cho, SooYoung Lee, Ki Sung Kwon, Byung Pil Lim, Myung-Shin Jeon, Eui Cheol Shin, Yong Sung Choi, Ella Fudim, Orit Picard, Miri Yavzori, Shomron Ben-Horin, Shin Jae Chang |
Journal | Journal of Crohn's & colitis
(J Crohns Colitis)
Vol. 11
Issue 5
Pg. 593-602
(May 01 2017)
ISSN: 1876-4479 [Electronic] England |
PMID | 28453766
(Publication Type: Journal Article)
|
Copyright | Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected] |
Chemical References |
- Antibodies, Monoclonal
- Biosimilar Pharmaceuticals
- CT-P13
- Cytokines
- Gastrointestinal Agents
- Tumor Necrosis Factor-alpha
- Infliximab
|
Topics |
- Antibodies, Monoclonal
(pharmacology, therapeutic use)
- Biosimilar Pharmaceuticals
(pharmacology, therapeutic use)
- Caco-2 Cells
(drug effects)
- Cytokines
(metabolism)
- Gastrointestinal Agents
(pharmacology, therapeutic use)
- Humans
- In Vitro Techniques
- Inflammatory Bowel Diseases
(drug therapy)
- Infliximab
(pharmacology, therapeutic use)
- Intestines
(cytology, drug effects, immunology)
- Macrophages
(drug effects)
- Tumor Necrosis Factor-alpha
(metabolism)
- Wound Healing
(drug effects)
|